Newsfile Corp
15 Sept 2026, 11:46 UTC · 2h ago
Verdict
Headline takes no side. We score OSTX +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
OS Therapies has achieved full alignment with the UK MHRA and EU EMA on its Conditional Marketing Authorisation Application (CMAA) for OST-HER2.
Newpress release dated September 15, 2026
So whatApproval in these regions serves as a catalyst for the ongoing BLA submission, increasing the probability of a positive FDA outcome by Q4 2026.
More positive than 98% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The company intends to commence a confirmatory Phase 3 trial in the fourth quarter of 2026.
Newpress release dated September 15, 2026
So whatInitiating this trial is a regulatory prerequisite for the CMAA, meaning a delay in Q4 would jeopardize European market entry.
More positive than 85% of claims this week
OS Therapies is eligible for a Priority Review Voucher (PRV) upon FDA BLA approval, with the most recent market sale for such vouchers at $220 million.
Priced inrefers to a sale in August 2026
So whatA successful sale would provide a non-dilutive cash infusion potentially exceeding $200M, significantly altering the company's balance sheet.
More positive than 77% of claims this week
The company intends to request Rolling Review of its BLA submission following a mid-September 2026 FDA meeting.
Newpress release dated September 15, 2026
So whatRolling Review can shorten the time to final FDA decision, potentially accelerating revenue generation into early 2027.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company achieved full regulatory alignment with the MHRA and EMA, paving the way for market authorization applications and a Phase 3 trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
1d ago
—
No price for OSTX right now — the quote feed didn't answer.
OSTX chart →
